Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

It's not a secret to market observers that pharmaceutical companies have embraced broadcast television and national spots to ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, ...

Learn about different types of eczema, symptoms, treatment options, and how to differentiate from other skin conditions.

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...

Sanofi (OTCMKTS:SNYNF – Get Free Report) was the target of a large decline in short interest in February. As of February 28th ...

We recently published a list of the 12 Best IPO Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Dupixent (dupilumab) – an IL-4 and IL-13 inhibitor – has dominated the market for biological therapies for atopic dermatitis since it was approved by the FDA in 2017.

Dupixent (dupilumab) is tipped to be the market leader among a new generation of inflammation drugs, analysts Evaluate Pharma forecasting it will hit sales of nearly $5 billion by 2022.

However, the biotech can rely on Dupixent, an eczema treatment it co-markets with Sanofi, to pick up much of the slack. In fact, despite the Eylea franchise's unimpressive performance in the ...